FLT3 inhibitors: clinical potential in acute myeloid leukemia

Acute myeloid leukemia (AML) is an aggressive hematopoietic malignancy that is cured in as few as 15%–40% of cases. Tremendous improvements in AML prognostication arose from a comprehensive analysis of leukemia cell genomes. Among normal karyotype AML cases, mutations in the FLT3 gene are the ones m...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Onco Targets Ther
Päätekijät: Hospital, Marie-Anne, Green, Alexa S, Maciel, Thiago T, Moura, Ivan C, Leung, Anskar Y, Bouscary, Didier, Tamburini, Jerome
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Dove Medical Press 2017
Aiheet:
Review
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC5304990/
https://ncbi.nlm.nih.gov/pubmed/28223820
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S103790
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia